1. Home
  2. FLYW vs URGN Comparison

FLYW vs URGN Comparison

Compare FLYW & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$17.60

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$46.94

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
URGN
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
FLYW
URGN
Price
$17.60
$46.94
Analyst Decision
Buy
Strong Buy
Analyst Count
14
7
Target Price
$16.21
$29.29
AVG Volume (30 Days)
2.2M
795.1K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
N/A
EPS
0.03
N/A
Revenue
$623,025,000.00
$1,128,000.00
Revenue This Year
$19.68
$129.09
Revenue Next Year
$15.25
$70.96
P/E Ratio
$580.50
N/A
Revenue Growth
26.59
N/A
52 Week Low
$10.55
$15.86
52 Week High
$18.98
$48.19

Technical Indicators

Market Signals
Indicator
FLYW
URGN
Relative Strength Index (RSI) 53.52 67.57
Support Level $17.29 $18.23
Resistance Level $18.05 N/A
Average True Range (ATR) 0.64 2.39
MACD 0.07 0.35
Stochastic Oscillator 59.94 86.58

Price Performance

Historical Comparison
FLYW
URGN

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: